MedTrace Logo

Bosentan and Pulmonary Endothelial Function

NCT01721564 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2016-10-19

Study results available
· View outcomes & findings →

Summary

6 months therapy of Bosentan, an endothelin antagonist, will lead to improvement in pulmonary microvascular endothelial function.

Conditions

Interventions

DRUG

Bosentan

62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months

Sponsors & Collaborators

  • Prof David S Celermajer

    lead OTHER

Principal Investigators

  • David S Celermajer, MBBS, PhD, DSc · Royal Prince Alfred Hospital, Sydney, Australia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2009-05-31
Completion
2009-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01721564 on ClinicalTrials.gov